Document Detail

Therapeutic termination of second trimester pregnancies with low dose misoprostol.
MedLine Citation:
PMID:  16827957     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the effectiveness of 50 microg misoprostol for midtrimester termination of pregnancies. DESIGN: Experimental, cross-sectional study. PLACE AND DURATION OF STUDY: Department of Gynaecology and Obstetrics, Unit II, Jinnah Postgraduate Medical Centre, Karachi, a tertiary care centre, from 1st Jan 2003 to 30th June 2005. PATIENTS AND METHODS: The study subjects were 54 pregnant women admitted during the 2nd trimester (14-26 weeks) of gestation, willing or requiring termination of pregnancy. Those patients were included in the study who were admitted with closed cervical os, either had intrauterine death, fetal anomaly, medical disorder (hypertension or diabetes) or history of previous ceasrean section. Cases of placenta previa, acute asthma, glaucoma, cardiac diseases and allergy to prostaglandins were excluded. Each patient received 50 microg misoprostol intravaginally. Maximum 4 doses were given at 4 hours interval and state of cervical os was assessed by vaginal examination before insertion of next dose or at the onset of uterine contractions. After 4 doses of misoprostol, patients were kept under observation and watched for uterine contractions to start or for expulsion of products. Syntocinon infusion was started to augment labour where products of conception failed to expel out inspite of open os. Outcome measures include success rate of termination within 12, 24, 36 and 48 hours, mean induction - abortion time interval and maternal side effects. RESULTS: The success rate of termination within 12, 24, 36 and 48 hours were 27.7%, 83.3%, 94.4% and 96.3% respectively. Mean induction to abortion time interval, in case of abortion within 48 hours, was found to be 18.9 +/- 11.58 (range 4 - 48 hours). Dead fetuses were aborted earlier than alive fetuses. The mean induction abortion time interval was 17.01 +/- 8.7 hours in dead and 23.4+/-15.9 hours in alive fetuses (t -value:1.9, p: 0.05). Two patients failed to deliver within 48 hours of induction. Two patients suffered from febrile illness. CONCLUSION: Vaginal administration of 50 microg misoprostol every 4 hourly is an effective and safe agent for ripening of cervix and convenient way of inducing abortion during 2nd trimester of pregnancy in a women either with alive or dead fetus. It is associated with a low frequency of side effect.
Nagina Fatima Liaquat; Iffat Javed; Samia Shuja; Tabassum Shoaib; Khadija Bano; Saima Waheed; Afia Ansar
Related Documents :
2916627 - Management of the third stage of labor in pregnancies terminated by prostaglandin e2.
7812997 - Termination of pregnancy using extra-amniotic prostaglandin f2a--experience in a periph...
11405987 - Oral misoprostol for induction of labour.
17432017 - Role of misoprostol for therapeutic termination of pregnancy from 10 -28 weeks of gesta...
2314777 - Potential human teratogenicity of frequently prescribed drugs.
1613337 - Fetal surgery: correction of anatomic and constitutional defects.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the College of Physicians and Surgeons--Pakistan : JCPSP     Volume:  16     ISSN:  1022-386X     ISO Abbreviation:  J Coll Physicians Surg Pak     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-07-10     Completed Date:  2006-10-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9606447     Medline TA:  J Coll Physicians Surg Pak     Country:  Pakistan    
Other Details:
Languages:  eng     Pagination:  464-7     Citation Subset:  IM    
Department of Obstetrics and Gynaecology, Jinnah Postgraduate Medical Centre, Karachi.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / administration & dosage*
Abortion, Therapeutic / methods*
Cross-Sectional Studies
Misoprostol / administration & dosage*
Pregnancy Trimester, Second
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in pat...
Next Document:  Role of thyroid peroxidase antibodies in the outcome of pregnancy.